IVERIC bio

IVERIC bio, a subsidiary of Astellas Pharma and formerly known as Ophthotech, is a biopharmaceutical company focused on developing therapies for the potential treatment of retinal disease.In April 2019, the company changed its name from Ophthotech to IVERIC bio.In April 2023, Astellas Pharma entered into a definitive agreement to acquire 100% of the outstanding shares of the company for USD 40.00 per share in cash for a total equity value of approximately USD 5.9 billion. The deal, subjected to closing conditions, was expected to be completed in the second quarter of Astellas' fiscal year 2023 (third calendar quarter of 2023). In July 2023, the transaction was completed and the company became a wholly-owned subsidiary of Astellas.In October 2018, the company had acquired Inception 4 and gained approximately USD 6.1 million in cash through Inception 4 and agreed to issue approximately 5.2 million shares to the shareholders of Inception 4. Through this acquisition, Ophthotech h